HER2-positive MBC has an average survival time of 40-65 months [9] and a five-year overall survival rate of 7% [7], and HER2-positive breast cancer that is metastatic at diagnosis (de novo metastasis) usually has a three-year survival rate of 50-70% [10]. Here, ERBB2 is linked to breast cancer.